All GLG News Analyses Filed Under: Ophthalmology

A possibly more effective contact lens disinfectant that what is currently available, but can it compete in real world trials.

This New York Times article describes many of the vision correction options available to individuals with presbyopia.  Because of the growing population of baby boomers, there is significant public interest in options that allow individuals freedom from reading glasses.  Multifocal contact...

This article presents the results of a study comparing standard phacoemulsification to Aqualase.  Complication rates were similar between the two procedures.  The 63 patient study looked in particular at foveal thickening after surgery.  While no statistical significance was demonstrated,...

Bausch & Lomb's SofPort Advanced Optics IOLs increased reimbursements will result in customer loyalty to the product and perhaps the brand name.

PDT remains a viable option for patients with new blood vessels from high myopia. Despite the era of antivegf therapy PDT may be safer in these patients than repeated injection. This article yet again defies another area for the use of PDT. PDT will be continued to be complemented to the currently available...

The Contact lens manufacturers have had similar torts over the years and people keep wearing contacts despite misrepresentations by the manufactures. The patients don’t care but pay more for the lenses in the end.

This article refers to an implanted glaucoma device that eliminates bleb formation for filtration. Blebs are fragile and represent a source for infection.  

Bausch and Lomb is doing a fine job recalling a product managing a problem that is not known to exist, as in harmful or unsafe to the public, so they are being cautious. There is nothing wrong with being cautious.

Elevated levels of Iron on a parts per billion level can cause chelating. Bausch & Lomb Voluntary Recall was wise for the firm.

There are implications that relate to the safety of the product ReNu MultiPlus contact lens solution.